PCV53 Trends in Prescription of P2Y12 Inhibitors Following Revascularization in Coronary Heart Disease

Secondary prophylaxis is essential to reduce the adverse cardiovascular outcomes post revascularization in coronary heart disease (CHD). P2Y12 inhibitors (i.e. clopidogrel, prasugrel, or ticagrelor) are effective for this purpose; however, guidelines which inhibitor prescribe differ according patient’s clinical characteristics, and trends their utilization not well studied real-world setting. The objective of study determine prescription patterns CHD patients. We utilized a retrospective cohort design using MarketScan Commercial Claims Database (2013-2018). included patients prescribed within 14 days index compare newer ticagrelor, prasugrel) with clopidogrel. In longitudinal cross-sectional trend analyses, we performed Cochrane-Armitage test see if there was significant change (at p=0.05) between three months' prevalence these agents from year 2013 2018. Among 92,734 identified patients, observed continuous decreased clopidogrel 65.5% 43.9% 2018; whereas ticagrelor use increased 13.6% 45.6%, replaced as most medication high bleeding risk, although decreasing, (50.6%) remained 12.0% 40.1% Additionally, (77.8%) preferred among stroke history. Importantly, prasugrel continued lose market-share time. found all time at p=0.05. Ticagrelor over years our data sample exceeded market share cases, that American Heart Association were reflected practice.